PCI logo from eps file.jpg
PCI Biotech Holding ASA: Annual Report 2022
28 avr. 2023 03h59 HE | PCI Biotech Holding ASA
Oslo, Norway, April 28, 2023The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2022. Please find the report attached, as well as the report according to the European...
PCI logo from eps file.jpg
PCI Biotech interim Q4 2022 results
17 févr. 2023 01h00 HE | PCI Biotech Holding ASA
Oslo (Norway), 17 February 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q4 2022 results. Please find enclosed the report and presentation. Highlights fimaNAc – dermatology and...
PCI logo from eps file.jpg
PCI Biotech: Invitation to Q4 2022 results presentation
13 févr. 2023 09h35 HE | PCI Biotech Holding ASA
Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q4 2022 interim report on Friday 17 February 2023, 08:30am – 09:30am CET (local time). The...
PCI logo from eps file.jpg
Flaggemelding relatert til PCIB
20 janv. 2023 06h37 HE | PCI Biotech Holding ASA
Myrlid AS har i dag, 20. januar 2023, solgt 450 000 aksjer i PCI Biotech Holding ASA ("Selskapet"). Som følge av salget innehar Myrlid AS etter dette totalt 1 450 000 aksjer og stemmer i Selskapet...
PCI logo from eps file.jpg
PCI Biotech: Employee share option scheme
25 nov. 2022 12h08 HE | PCI Biotech Holding ASA
Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.         In accordance with the authorisation granted by the...
PCI logo from eps file.jpg
PCI Biotech interim Q3 2022 report
23 nov. 2022 01h00 HE | PCI Biotech Holding ASA
Oslo (Norway), 23 November 2022 – PCI Biotech (OSE: PCIB), today announces its interim Q3 2022 results. Please find enclosed the report and presentation. Highlights Corporate*Efforts to finance a Ph...
PCI logo from eps file.jpg
PCI Biotech: Invitation to Q3 2022 results presentation
17 nov. 2022 11h42 HE | PCI Biotech Holding ASA
Oslo, Norway, 17 November 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q3 2022 interim report on Wednesday 23 November 2022, 08:30am – 09:30am CET (local time). ...
PCI logo from eps file.jpg
Correction: PCI Biotech: Mandatory notification regarding trade of shares
08 sept. 2022 05h58 HE | PCI Biotech Holding ASA
Borkenholm AS has on 8 September 2022 purchased 4,000 shares in PCI Biotech Holding ASA ("PCI Biotech") at an average price of NOK 1.948 per share. Borkenholm AS is a related party to board member...
PCI logo from eps file.jpg
PCI Biotech: Mandatory notification regarding trade of shares
08 sept. 2022 05h03 HE | PCI Biotech Holding ASA
Borkenholm AS has on 8 September 2022 purchased 4,000 shares in PCI Biotech Holding ASA ("PCI Biotech") at an average price of NOK 1.948 per share. Borkenholm AS is a related party to board member...
PCI logo from eps file.jpg
PCI Biotech interim first-half year 2022 results
31 août 2022 01h00 HE | PCI Biotech Holding ASA
Oslo (Norway), 31 August 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first-half year 2022 results. Please find enclosed the report and...